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Abstract 1	
Class imbalance occurs frequently in drug discovery datasets. In oral absorption datasets, in 2	
the literature, there are considerably more of highly-absorbed compounds compared with 3	
poorly-absorbed compounds. This produces models that are biased towards highly-absorbed 4	
compounds which lack generalization to industry settings where more early stage drug 5	
candidates are poorly-absorbed. This paper presents two strategies to cope with unbalanced 6	
class datasets: Under-sampling the majority high absorption class and misclassification costs 7	
using classification decision trees. The published dataset by Hou et al (2007), which 8	
contained percentage human intestinal absorption of 645 drug and drug-like compounds, was 9	
used for the development and validation of classification trees using C&RT analysis. The 10	
results indicate that under-sampling the majority class, highly-absorbed compounds, leads to 11	
a balanced distribution (50:50) training set which can achieve better accuracies for poorly-12	
absorbed compounds, whereas the biased training set achieved higher accuracies for highly-13	
absorbed compounds. The use of misclassification costs resulted in improved class 14	
predictions, when applied to reduce false positives or false negatives. Moreover, it was shown 15	
that the classical overall accuracy measure used in many publications is particularly 16	
misleading in the case of unbalanced datasets and more appropriate measures presented here 17	
may be used for a more realistic assessment of the classification models’ performance. Thus, 18	
these strategies offer improvements to cope with unbalanced class datasets to obtain 19	
classification models applicable in industry.  20	
 21	
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1. Introduction 1	
Good intestinal absorption is important for oral administration of many drugs in the 2	
pharmaceutical industry due to ease of administration and convenience for the patient. The 3	
effort to reduce costs and animal testing has resulted in numerous minimisations of assays to 4	
become high-throughput1, 2. In tandem with these or as an alternative for high-throughput 5	
screening assays in early drug discovery, in silico modelling using QSAR (Quantitative 6	
Structure-Activity Relationships) has been successfully utilised for the prediction of ADMET 7	
(absorption, distribution, metabolism, elimination and toxicity) properties, particularly 8	
intestinal absorption3, 4. QSAR models can act as a tool to filter and highlight undesirable 9	
compounds or be used as guidance to help select appropriate assays for the next stage of the 10	
drug discovery cascade based on chemical structure and physiochemical properties alone 5, 6. 11	
 12	
Datasets in the literature used to predict or classify intestinal absorption are highly biased 13	
towards highly-absorbed compounds. This is due to the larger numbers of highly-absorbed 14	
compounds amongst the marketed drugs that constitute the datasets7, 8. The largest publically 15	
available database complied by Hou et al (2007) contains over 80% of compounds with 16	
human intestinal absorption values of over 50%. There are a number of reasons for this: the 17	
vast majority of percentage human intestinal absorption (%HIA) data is obtained from 18	
clinical trials where it is expected for compounds to have good absorption in order to have 19	
reached this stage, and the lack of published data representing poorly-moderately absorbed 20	
compounds2, 9, 10. These biased datasets are not representative of a true industry scenario at 21	
present, where there are more drug candidates with poor absorption. With advances of 22	
technology, many of the drugs designed today are bigger and more lipophillic, leading to 23	
compounds with low absorption due to solubility issues11. Imbalanced datasets are a problem 24	
for modelling. Any QSAR model produced from a biased dataset will in turn be biased itself 25	
to the prediction of the majority class (in this case high absorption class) and will be poorly 26	
predictive for the poorly-absorbed compounds.  27	
In order to resolve this, a number of techniques can be carried out to cope with the class 28	
imbalance of the dataset. The first technique is to under-sample the majority class (highly-29	
absorbed compounds) in the training set. The problem with this method is the reduction in 30	
data utilised for model building, therefore there could be a problem with generalization to 31	
new compound sets. This could be resolved by using a bootstrapping technique or bagging12. 32	
These methods are often used to improve the statistical accuracy and robustness of 33	
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predictions, regardless of whether or not the dataset shows class imbalance. However, using a 1	
specific version of these methods that under-samples the majority class at all the sampling 2	
steps, they may be used to overcome the imbalanced data distribution problem. Ensemble 3	
methods such as random forest13 provide consensus predictions which may have improved 4	
accuracy. The problem with bootstrapping and ensemble methods in relation to our work is 5	
that they use multiple training sets and therefore multiple decision trees (or classification 6	
trees) will be produced, which will increase the complexity and reduce interpretability of the 7	
models. Hence, in this work we focus on producing classification models that consist of a 8	
single decision tree, to facilitate the interpretability of the model.  9	
Another problem with under-sampling is that in order to assess the predictability of the 10	
balanced training set fairly, the validation set will also have to be adjusted to mirror the 11	
training set in terms of distribution of the data, but again this reduces the dataset size in the 12	
validation set and increases the variability of the results14. However the models built using 13	
this equal distribution should be better models to predict both poorly and highly-absorbed 14	
compounds if a big enough dataset is used.  15	
The second technique applicable to unbalanced class datasets is to increase the cost of 16	
misclassification of the minority class. In binary classification there are two types of 17	
misclassification, which can be summarised using Figure 1.  18	
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Figure 1.  Possible outcomes of a binary classification 20	
A poorly-absorbed compound misclassified into the highly-absorbed class would be a false 21	
positive, and a highly-absorbed compound misclassified into a poorly-absorbed class would 22	
be a false negative. Misclassification costs may be defined by the user in the algorithm in 23	
order to predict classes that maximise the misclassification cost for false positive or false 24	
negatives. An example of this can be shown graphically in Figure 2. 25	
5	
	
  Observed class 
  HIGH LOW 
Predicted 
class 
HIGH NO COST 2 
LOW 1 NO COST 
 1	
Figure 2.  A classification matrix showing higher misclassification cost assigned to false 2	
positives 3	
According to Figure 2, if the algorithm attempts to misclassify the poorly-absorbed 4	
compound into the highly-absorbed class, there will be a higher cost associated with this 5	
misclassification in comparison with the misclassification of a highly-absorbed drug into a 6	
poor absorption group. By increasing the cost for misclassification in this example to two the 7	
number of false positives should be reduced. The cost assigned to the misclassification can be 8	
subjective. However, to assign a number objectively, the class distribution of the high and 9	
poorly-absorbed compounds of the training set should be considered by giving a higher cost 10	
to the misclassification of poorly-absorbed compounds, the minority class. 11	
In drug discovery there has been a lot of debate on what error to reduce, as both false 12	
positives and false negatives have a detrimental effect. The reduction of either one of these 13	
errors will depend on the nature of the problem and the intended outcomes, whether this be 14	
dependent on business or scientific needs. However, careful consideration on which one to 15	
focus on is needed at the start of the project15. False negatives give rise to missed 16	
opportunities of potential new blockbuster drugs. A potential drug could be dismissed in early 17	
library screens as having low absorption when in fact it has high absorption, which is ideal 18	
for oral administration3. Amlodipine is an example of this, using QSAR it was predicted to 19	
have poor bioavailability however it has high observed oral bioavailability16. Even if an 20	
active compound like Amlodipine is missed and predicted incorrectly, it is less problematic if 21	
there are similar compounds in the compound library that are predicted as active and carried 22	
through; but problems arise when unique novel chemicals with no similar compounds are	23	
missed completely. Despite this, as emphasised by Klopman (2002) care should be taken with 24	
the prediction models to avoid overlooking false negatives for the advantage of  shortening 25	
the drug discovery process 17. Reducing the number of false positives could be considered 26	
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equally as important or more important for cost-effectiveness reasons. If a drug is 1	
misclassified as highly-absorbed when in fact it is poorly-absorbed, more time, effort and 2	
money is invested to investigate and reveal the compound’s true class with further tests. 3	
Although there are few publications indicating that false positives need to be decreased rather 4	
than false negatives, with the spiralling cost of drug discovery it may be a future 5	
consideration for many companies to become more cost-effective. To conclude, although 6	
Cummings (2006)18 states that the trend is to reduce the number of false positives and to put 7	
up with the number of false negatives15, a suitable balance depending on the context of the 8	
problem and the intended outcomes may be the answer to reduce time and money testing 9	
unsuitable drugs compared with reducing the potential for missed opportunities of new drug 10	
candidates, as long as there are still a high number of true positives being discovered15, 19. 11	
The aim of this work was to use methods specifically designed for coping with unbalanced 12	
class datasets in order to improve the classification accuracy of %HIA into high and low 13	
classes and finding the best classification model using the Classification & Regression Trees 14	
(C&RT) method.  15	
The main dataset used for this work consisted of %HIA data of 645 drugs and drug-like 16	
compounds20. As stated previously this dataset is biased towards the number of highly-17	
absorbed compounds. In this work two different training sets were randomly selected from 18	
this initial dataset, the balanced training set 1 (TS1) contained roughly a 50:50 ratio of highly 19	
and poorly-absorbed compounds and the unbalanced training set 2 (TS2) contained roughly 20	
an 85:15 ratio of highly and poorly-absorbed compounds respectively.  21	
TS1, having an equal balance of high and poor absorption compounds will be used to show 22	
the effects of under-sampling the majority class compared with TS2, the unbalanced dataset. 23	
TS1 will also be used to compare the effects of various misclassification cost ratios for 24	
reducing either false positives or false negatives. As the TS1 dataset is balanced there is no 25	
bias towards reducing either one of these errors, so the effects of misclassification costs will 26	
be shown. As shown with the previous discussion regarding which error to reduce, either 27	
false positives or false negatives, there is no general consensus,  so applying misclassification 28	
costs to reduce either error and seeing the results is justified. TS2, containing a higher 29	
proportion of highly-absorbed compounds is already biased towards reducing the number of 30	
false negatives, so misclassification costs should be assigned to reduce the number of false 31	
positives only (by assigning a higher cost to FPs). 32	
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2. Methods and Materials 1	
2.1 Dataset 2	
The dataset used consisted of %HIA data for 645 drugs and drug-like compounds extracted 3	
from SDF format from the supporting information provided 20. In this research the 26 4	
compounds containing a quaternary ammonium were removed entirely due to a number of 5	
missing molecular descriptors significant to absorption, such as logD, for these compounds; 6	
and STATISTICA software would automatically remove compounds with any missing data.20, 7	
21. 8	
Two training sets and corresponding validation sets were selected from this dataset; training 9	
set 1 (TS1) containing roughly a 50:50 ratio, and training set 2 (TS2) containing roughly an 10	
85:15 ratio of highly and poorly-absorbed compounds. The same class distribution for the 11	
corresponding validation sets was applied to create a fairer more controlled validation for the 12	
models. The exact compound numbers and class distributions are shown in Table 1. 13	
Table 1. Compound numbers and class distribution for both training set scenarios 14	
		
Number of 
Compounds 
Class Distribution           
(Ratio of High/Low 
absorption compounds) 
Dataset Training set 
Validation 
set Training set Validation set 
TS1 94 89 50:50 50:50 
TS2 517 102 85:15 85:15 
 15	
TS1 is the balanced training set containing about 10 drugs in each 10% range of %HIA. The 16	
training set was selected randomly by under-sampling the majority class (highly-absorbed 17	
compounds). For the validation set, the remaining compounds were also under-sampled to 18	
mimic the data distribution of the training set. 19	
TS2 is the unbalanced training set selected randomly after compounds were sorted by 20	
ascending %HIA values and then by logP values. The ascending %HIA values were put into 21	
groups of six, then 5/6th of these compounds were placed in the training set and the remaining 22	
into the validation set. This set is unbalanced as it contains a higher number of the high 23	
absorption class.  24	
2.2 Molecular descriptors 25	
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A variety of different software packages were used to compute molecular descriptors; they 1	
include TSAR 3D v3.3 (Accelrys Inc), MDL QSAR (Accelrys Inc.) and Advanced Chemistry 2	
Development ACD Labs/ LogD Suite v12. Due to software limitations some molecular 3	
descriptors could not be calculated for some compounds in the dataset. A total of 215 4	
descriptors were used in this study. 5	
2.3 Classification and Regression Trees (C&RT) 6	
STATISTICA v11 (StatSoft Ltd) software was used for classification of compounds using 7	
C&RT analysis. According to observed %HIA values in the dataset, compounds were placed 8	
into either the ‘High’ class if %HIA was equal to or greater than 50% or the ‘Low’ class, 9	
if %HIA was less than 50%.  10	
C&RT analysis is a statistical technique that uses decision trees to solve regression and 11	
classification problems developed by Breinman et al (1984). If the dependant variable is 12	
categorical then a classification tree is made (e.g. predicting low or high absorption classes) 13	
and if the dependant variable is continuous then a regression tree is produced resulting in the 14	
prediction of numeric %HIA values for all compounds22, 23.  15	
The binary C&RT analysis starts building the decision tree at the ‘tree root’ using molecular 16	
descriptors. The algorithm in C&RT will choose the most appropriate (statistically significant) 17	
molecular descriptor to split the tree and the threshold value to define the split. A parent node 18	
splits into two child nodes and then these become the parent groups for the next split. The 19	
splitting of the tree continues until it can be no longer split due to stopping factors being 20	
applied to prune the tree to prevent over-fitting. The nodes which cannot be split anymore are 21	
termed terminal nodes23, 24, and they contain the predicted classes. 22	
For this work, HIA Class was set as the dependant categorical variable and all 215 molecular 23	
descriptors were selected as continuous independent variables. Furthermore, pre-selected 24	
subsets of descriptors were used in the analysis. Molecular descriptors were: 1) those chosen 25	
by linear stepwise regression and 2) descriptors of Lipinski’s rule of five including number of 26	
rotatable bonds. Using MINITAB Statistical Software (version 15.1.0.0) linear stepwise 27	
regression analysis was performed using the training set TS1 to obtain descriptor sets 1 and 2 28	
and using the training set TS2 to obtain descriptor set 3. During CART analysis, models were 29	
created using descriptor sets 1 and 2 for TS1 and descriptor set 3 for TS2. This ensured that 30	
the validation set was never used at any stage of model development and remained intact for 31	
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the validation of the models. Moreover, Lipinski’s ‘rule of five descriptors’ were used in 1	
CART analysis using both TS1 and TS2. 2	
Stopping factors defined in the software will not split a parent node into child nodes if there 3	
are less than 10 or 40 compounds in the parent node for TS1 and TS2, respectively. The 4	
selection of these stopping factors was based on the statistical performance of the models for 5	
the training set as defined by sensitivity (SE), specificity (SP) and SP × SE (defined below). 6	
If there was only one compound in a terminal node of a tree, manual pruning was carried out 7	
to prevent this final split so that no terminal nodes contained only one compound. In order to 8	
cope with missing values in C&RT analysis, STATISTICA can find the next best split 9	
variable (molecular descriptor) which is used when the split variable has missing values. The 10	
next best split variable (‘surrogate’) that is chosen is the one that correlates the most with the 11	
original one. In this case the optional setting of two surrogates was selected; so if the original 12	
variable is missing then the first surrogate variable was used and if this was also missing then 13	
the second surrogate variable was used for splitting25. If the original variable plus the two 14	
surrogates are missing then the compound is removed from the tree. All other settings used 15	
were default setting defined by the software. 16	
2.4 Misclassification costs  17	
The aim of a decision tree building algorithm is to create the best model with the lowest total 18	
misclassification cost over all compounds in the validation set. By applying varying costs to 19	
certain misclassifications (either false positives or false negatives) it is possible to reduce the 20	
number of misclassifications due to the higher cost. This study compared the use of the same 21	
costing with higher costing to reduce either false positives or false negatives. 22	
For TS1, the balanced dataset, a misclassification cost of two was applied to either reduce 23	
false positives or false negatives. As TS2 is unbalanced due to the class distribution of the 24	
dataset towards the highly-absorbed compounds (85:15), a misclassification cost ratio of 4:1 25	
was applied to false positive:false negatives. It must be noted that due to the class 26	
distributions for TS2 the dataset is already biased towards reducing false negatives, as there 27	
are more highly-absorbed compounds than poorly-absorbed. 28	
2.5 Statistical significance of the models 29	
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The predictive performance of classification was measured using Specificity (SP), Sensitivity 1	
(SE), the cost normalised misclassification index (CNMI) and SP × SE. These terms have 2	
been defined below.  3	
Specificity is the ratio of correct classifications of poorly-absorbed compounds (SP = 4	
TN/(TN+FP)). In this equation TN is the number of true negatives and FP is the number of 5	
false positives. Specificity is inversely proportional to the number of false positives. 6	
Sensitivity indicates the correct number of classifications for the highly-absorbed compound 7	
class (SE = TP/(TP+FN)), where TP is the number of true positives and FN is the number of 8	
false negatives. Sensitivity is inversely proportional to the number of false negatives. Overall 9	
accuracy is often defined as the number of correct predictions (true positives and true 10	
negatives) divided by the total number of compounds in the validation set. However, this 11	
calculation is not suitable to use for this work when the dataset is highly biased. In this case 12	
the overall accuracy will be unduly influenced by the classification accuracy of the majority 13	
class, the highly absorbed compounds (SE). In this work, in order to represent the overall 14	
predictive performance, specificity multiplied by sensitivity was used (SP × SE). SP × SE, 15	
although not a very common measure in QSAR, is useful in this case since the data is highly 16	
biased. 17	
The cost normalised misclassification index (CNMI) was calculated using Equation 1. The 18	
numerator of this equation is calculated by first multiplying the number of each type of 19	
misclassifications (false positives and false negatives) by the corresponding misclassification 20	
cost and then adding those two products. The denominator (normalization factor) is 21	
calculated by first multiplying the total number of compounds in each class – i.e. number of 22	
negatives (poorly-absorbed compounds) and number of positives (highly-absorbed 23	
compounds) – by the corresponding misclassification costs and then adding those two 24	
products. 25	 !"#$ = &'	×	*+,-&' . &/	×	*+,-&//01	×	*+,-&' . '+,	×	*+,-&/ 																																																																																				Eq. 1          	26	
CostFP and CostFN are the misclassification cost assigned for false positives or false negatives 27	
and Neg is the total number of poorly-absorbed compounds and Pos is the total number of 28	
highly-absorbed compounds. Note that the numerator of Equation 1 is the total 29	
misclassification cost obtained by using a classification model to classify compounds in the 30	
validation set, whilst the denominator is the maximum misclassification cost that could in 31	
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principle be achieved (if all compounds in the validation set were misclassified). Hence, the 1	
calculated value will be between zero and one, with zero representing no misclassification 2	
errors, as the number increases to one then the misclassifications of the model increase.  3	
3. Results 4	
Predictive models for classification of drug candidates into high and poor absorption groups 5	
are very useful in drug discovery. Unbalanced distribution of data in the available datasets 6	
has been a drawback which has traditionally complicated the model development activities. 7	
In this work two different training sets with different data distributions and various 8	
misclassification costs were used to develop classification trees using the C&RT routine in 9	
STATISTICA software. In all result tables the highest SP, SE, SP × SE and the lowest CNMI 10	
for the validation sets are highlighted in bold. When comparing the models it must be noted 11	
that the most significant molecular descriptors selected for splitting the data by the C&RT 12	
algorithm will be affected by the class distribution of the training sets, so for TS1 and TS2 13	
with different class distributions different significant descriptors could be picked. Moreover, 14	
when comparing models developed using the same training set CNMI maybe a more suitable 15	
performance measure since it is normalised for the cost ratios of false positives and false 16	
negatives. 17	
3.1. C&RT classification analysis for TS1 18	
Classification using C&RT analysis was carried with the same or different misclassification 19	
costs to reduce either false positives or false negatives. Initially all 215 molecular descriptors 20	
were set as independent variables and HIA class was set as the dependant categorical variable. 21	
In this way C&RT algorithm selects the most significant descriptor out of all 215 for each 22	
split. These trees were compared with C&RT trees created by using smaller descriptor sets 23	
selected previously by stepwise linear regression using TS1 (descriptor sets 1 and 2), TS2 24	
(descriptor set 3) or descriptors related to Lipinski’s rule of five plus number of rotatable 25	
bonds26 (descriptor set 4). The preselected descriptor sets are shown in the Supporting 26	
Information. 27	
Table 2 shows the predictive performance measures of the classification trees for TS1 28	
obtained with different misclassification costs using all descriptors and descriptor sets 1-4 in 29	
the supporting information. Recall that SE, SP and SP × SE measures should be maximized, 30	
whilst the CNMI measure should be minimized. 31	
32	
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Table 2. The results of C&RT Classification analysis using different descriptor sets and 1	
misclassification costs ratios for TS1 2	
Model Cost           FP:FN 
Descriptor 
Set Set 
N 
validation 
set 
SP × SE SE SP CNMI 
1 
1:1 
ALL 
t 
83 
0.899 0.981 0.917 0.045 
v 0.598 0.733 0.816 0.229 
2 1 
t 
89 
0.939 0.962 0.976 0.032 
v 0.625 0.714 0.875 0.213 
3 2 
t 
89 
0.951 1.000 0.951 0.021 
v 0.657 0.796 0.825 0.191 
4 4 
t 
89 
0.828 0.943 0.878 0.085 
v 0.300 0.857 0.350 0.371 
5 
2:1 
ALL 
t 
83 
0.962 0.962 1.000 0.014 
v 0.404 0.667 0.605 0.352 
6 1 
t 
89 
0.939 0.962 0.976 0.027 
v 0.547 0.592 0.925 0.188 
7 2 
t 
89 
0.981 0.981 1.000 0.007 
v 0.604 0.755 0.800 0.203 
8 4 
t 
89 
0.920 0.943 0.976 0.034 
v 0.597 0.796 0.750 0.217 
9 
1:2 
ALL t 83 0.872 0.981 0.889 0.048 
v 0.635 0.778 0.816 0.223 
10 1 
t 
89 
0.885 0.981 0.902 0.044 
v 0.686 0.857 0.800 0.165 
11 2 
t 
89 
0.951 1.000 0.951 0.015 
v 0.657 0.796 0.825 0.209 
12 4 
t 
89 
0.829 1.000 0.829 0.052 
v 0.438 0.796 0.550 0.295 
FP = False positive; FN = False negative; SE= Sensitivity, SP = Specificity; CNMI = Cost normalised 3	
misclassification index; N validation is the number of validation set compounds that was predicted by the model 4	
In Table 2, a cost ratio of 2:1 for FP:FN indicates that a double misclassification cost has 5	
been applied for the misclassification of poorly-absorbed compounds compared with the 6	
misclassification of highly-absorbed compounds and so forth. Therefore, in this case, the 7	
expectation is a reduction in the number of false positives (increased specificity). 8	
In order to see the effect of cost ratios, one should compare the performance measure values 9	
of the models generated using the same descriptor set. It can be seen in Table 2 that when all 10	
descriptors were used in the analysis (models 1, 5 and 9) better predictive accuracy is 11	
obtained when misclassification costs are adjusted to reduce false negatives (model 9). In this 12	
case the SP × SE increased from 0.598 in model 1 to 0.635 in model 9 and the sensitivity was 13	
13	
	
the highest at 0.778. The CNMI also decreased from 0.229 (model 1) to 0.223 (model 9). 1	
This indicates that by applying costs to reduce false negatives a more accurate C&RT model 2	
has resulted. The decrease in false negatives (higher sensitivity value) was expected as 3	
misclassification costs were to improve the class prediction of highly-absorbed compounds; 4	
however the specificity decreased.  The classification tree (model 9) has been presented in 5	
Figure 3. The C&RT trees presented in this paper show on the tree where manual pruning 6	
has been carried out. In Figure 3, tree manual pruning was not needed. 7	
	8	
Figure 3. Tree graph for the best C&RT model selecting all molecular descriptors using TS1 9	
training set with misclassification costs applied to reduce false negatives (Model 9) 10	
Furthermore, the molecular descriptors chosen by linear stepwise regression for the 11	
estimation of %HIA26 (descriptors sets 1 and 2) and descriptors of Lipinski’s rule of five 12	
including number of rotatable bonds (descriptor set 4) were also used in C&RT analysis. 13	
Table 2 shows that the model obtained using descriptor set 1 is the best model (model 10). 14	
The fact that most models that are obtained using a pre-selected descriptor sets have better 15	
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prediction accuracy indicates that such descriptor selection methods may be better than the 1	
descriptor selection algorithm in C&RT. This may be due to the smaller number of chemicals 2	
in lower nodes of the tree that are used for the selection of the best descriptor for further splits 3	
in C&RT. Model 10 achieved an SP × SE of 0.686, sensitivity value of 0.857 and a 4	
specificity value of 0.800 when using a cost ratio of 1:2 for FP:FN. This model has been 5	
shown in Figure 4. It is interesting to note in Table 2 that specificity is much better with the 6	
model obtained with higher cost for the false positives, using descriptor set 1, which shows 7	
that the misclassification costs are having the expected effect on the model.  8	
 9	
Figure 4. Tree graph for C&RT analysis using TS1 with misclassification costs applied to 10	
reduce false negatives using descriptor set 1 (Model 10) - the dashed box around the nodes 11	
indicates pruning of the original tree	12	
There is a general pattern when misclassification costs are applied to either reduce false 13	
positives or false negatives in the majority of models (Table 2). When higher 14	
misclassification costs are applied to reduce false positives the specificity values are higher or 15	
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equal to models where similar costs are applied, with only a few exceptions. On the other 1	
hand, false negative values decrease upon assigning higher misclassification costs on false 2	
negatives, resulting in higher or equivalent to FP:FN 1:1 ratio sensitivity values.  3	
Interpretation of the selected models based on TS1 4	
In the tree in Figure 3 the first split variable is SHHBd, which is the sum of the E-State 5	
indexes for hydrogen bond donors. This molecular descriptor is linked to the number of 6	
hydrogen bond donors highlighted in Lipinski’s rule of five27, which states that a molecule 7	
will be highly likely to be poorly-absorbed if two or more of the following rules are broken: 8	
if molecular weight >500 Da, sum of OH and NH hydrogen bond donors >5, calculated logP 9	
(ClogP) >5 and sum of N and O atoms as hydrogen bond acceptors >10. The cut off point for 10	
SHHBd is 7.81, which corresponds to roughly 3 or more hydrogen bond donor groups. 11	
Compounds with low hydrogen bonding donor ability (low SHHBd value) will have poor 12	
absorption if ABSQ, the sum of absolute values of atomic partial charges of the molecule28 is 13	
high (node 5). This indicates that molecules or compounds with electronegative or positive 14	
atoms (molecules containing heteroatoms) will be less absorbed through the intestine. This is 15	
in agreement with the hydrogen bond acceptor factor in Lipinski’s rule of five. The 16	
compounds with low number of heteroatoms (ABSQ) will have high absorption unless they 17	
are highly acidic and have high acidic ionization at pH 1 (FiA1 > 0.139). It has been well 18	
cited that drugs that are unionised will pass through the intestinal membrane27, 29. 19	
The next important descriptor selected by the C&RT for the partitioning of highly hydrogen 20	
bond donor compounds is VAMP HOMO, which is the energy of the highest occupied 21	
molecular orbital calculated by AM1 semi empirical method and has been used in previous 22	
QSAR models for bioavailability30. According to this split, compounds with HOMO energy 23	
of <= -9.22 are all poorly-absorbed compounds. These are highly polar molecules containing 24	
many hydrogen bonding groups (SHHBd) and few or no double bonds – e.g bisphosphonates 25	
and macrolides. The high HOMO energy group (Node 7) on the other hand, consists mainly 26	
of compounds of moderate absorption level (HIA of 40-60%) and, although marked as 27	
highly-absorbed, contains more of the poorly-absorbed compounds to be classified at the next 28	
level. These compounds are also of polar nature with many hydrogen bonding groups, but 29	
they also have planar areas in the molecule resulting from aromatic groups or other 30	
conjugated double bonds (hence high HOMO energy)31. High HOMO energy compounds at 31	
Node 7 will have high absorption provided that they have dipole moment > 6.63. An 32	
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inspection of these compounds at Node 9 shows that these are mainly natural or semi-1	
synthetic compounds e.g. a peptide or a sugar like structure. These compounds may be 2	
absorbed by carrier systems due to resemblance to natural metabolites. Examples of these are 3	
oxytetracycline, which contains an aromatic system with many oxygen and nitrogen 4	
functional groups and is a known substrate of human organic anion transporters32 or 5	
dipyridamole transported via nucleoside transporters in the small intestine33.    6	
For Figure 4 (model 10), although all of the eight descriptors of descriptor set 1 were used as 7	
independent continuous variables in the C&RT analysis, not all of them were used to build 8	
the tree in Figure 4; in fact only six out of the eight were used with SHBin7 and SsCH3 not 9	
being selected. Similar to model 9, SHHBd is the first split variable in this model. The highly 10	
hydrogen bond (according to SHHBd), low absorption group (node 3) has been partitioned 11	
again according to SpcPolarizability, which has replaced VAMP HOMO in the previous 12	
model (Figure 3). SpcPolarizability defines how readily the molecular charge distribution on 13	
a molecule, which is the sum of the electronic structure of the individual atoms of the 14	
compound, is affected by external oscillating fields. Compounds with low SpcPolarizability 15	
values have been divided into groups according to their SHBint2 values. SHBint2 is the sum 16	
of E-state indexes for hydrogen bonding groups of path length 2 34 and is high in compounds 17	
like saquinavir and ceftriaxone with peptide bonds. If this value is high then compounds will 18	
be classed into the poor absorption class. Compounds with low SHHBd (node 2) have also 19	
been partitioned according to SHBint2, with chemicals containing a low number of hydrogen 20	
bonding groups of two bond distance showing high oral absorption probability (node 4). 21	
Compounds with high SHBint2 may still have high oral absorption if ‘inertia moment 2 size’ 22	
(a size related descriptor) has a low value and ACDlogD5.5 (lipophilicity descriptor) value is 23	
high (node 11) and ACD_Density (molecular density) value is small (node 12). Descriptors 24	
relating to molecular size have been inversely related to intestinal absorption, therefore the 25	
larger the molecule the lower the absorption35. The relationship with logD (a measure of 26	
hydrophobicity at a specific pH6) is in accordance with previous literature35-38. ACD Density 27	
is the mass per unit volume of a molecule; density will be high for molecules containing 28	
many heteroatoms. Compounds with a high density will have low absorption31, which is also 29	
true according to this tree. Pruning of this tree was carried out as there were child nodes with 30	
only one compound in them as shown in Figure 4.  31	
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3.2 C&RT classification analysis for TS2 1	
C&RT classification analysis with misclassification costs was also carried out on TS2, the 2	
unbalanced dataset, to see if error rates can be reduced. As there are a larger number of 3	
highly-absorbed compounds compared to poorly-absorbed compounds, the misclassification 4	
costs to reduce the number of false negatives need not be applied as the class distribution of 5	
TS2 already favours the decrease of false negatives. Therefore misclassification costs are 6	
applied for reducing false positives only. The costing of 4 was applied to false positives 7	
(keeping the baseline cost of 1 for false negatives), as this was considered the most suitable 8	
number based on the class distribution of roughly 4:1 for high to low absorption compounds. 9	
The results of the C&RT classification analysis for TS2 are shown in Table 3. 10	
Table 3. The results of C&RT Classification analysis using different descriptor sets and 11	
misclassification costs ratios for TS2 12	
Mod
el 
Cost           
FP:FN 
Descriptor 
Set Set 
N 
Validation 
set 
SP × SE SE SP CNMI 
13 1:1 ALL 
t 
94 
0.862 0.955 0.903 0.053 
v 0.400 0.880 0.455 0.170 
14 1:1 3 
t 
102 
0.704 0.973 0.724 0.064 
v 0.445 0.954 0.467 0.118 
15 1:1 4 
t 
102 
0.620 0.982 0.632 0.070 
v 0.451 0.966 0.467 0.108 
16 4:1 ALL 
t 
94 
0.861 0.873 0.986 0.033 
v 0.660 0.807 0.818 0.070 
17 4:1 3 
t 
102 
0.879 0.890 0.987 0.028 
v 0.653 0.816 0.800 0.077 
18 4:1 4 
t 
102 
0.855 0.890 0.961 0.033 
v 0.517 0.862 0.600 0.099 
FP = False positive; FN = False negative; SE= Sensitivity, SP = Specificity; CNMI = Cost normalised 13	
misclassification index; N validation is the number of validation set compounds that was predicted by the model 14	
Table 3 shows that when all descriptors were available to C&RT analysis the best results 15	
were achieved when applying misclassification costs to reduce false positives (comparing 16	
model 13 and 16). As expected, specificity increases and misclassification error rate 17	
decreases when misclassification costs were applied. By applying misclassification costs to 18	
increase specificity, the sensitivity of the model will decrease (Table 3). Figure 5 shows the 19	
best model when all descriptors were supplied and the significant descriptors were selected 20	
by C&RT analysis (model 16). 21	
18	
	
 1	
Figure 5.  Tree graph for the best C&RT analysis using TS2 using all descriptors with misclassification costs applied to reduce false positives 2	
(Model 16) - the dashed box around the nodes denotes pruning of the original tree 3	
Tree graph for HIA CLASS
Num. of non-terminal nodes: 13,  Num. of terminal nodes: 14
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As with the TS1, C&RT analysis was carried out using the pre-selected molecular 1	
descriptors26 (Table 2). Table 3 shows that the best pre-selected descriptor set was descriptor 2	
set 3 (model 17) when considering SP × SE. The classification tree model 17 is shown in 3	
Figure 6. With misclassification costs to reduce false positives the tree had the highest 4	
specificity (0.800) and also the lowest CNMI (0.077). Depending on the use of the model, if 5	
the reduction of false positives (increase of specificity) is the intention then using 6	
misclassification costs will increase the specificity for descriptor set 3 from 0.467 to 0.800; 7	
however, sensitivity decreases from 0.954 to 0.816. 8	
	9	
Figure 6. Tree graph for C&RT analysis using TS2 with misclassification costs applied to 10	
false positives (FP:FN 4:1) using descriptor set 3 (Model 17)  11	
Interpretation of selected models based on TS2 12	
	 Tree graph for HIA CLASS
Num. of non-terminal nodes: 8,  Num. of terminal nodes: 9
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Figure 5 shows the selected tree when C&RT analysis selected the descriptors from all the 1	
supplied descriptors (model 16). Similar to models 9 and 10 obtained using TS1, this tree 2	
involves the hydrogen bond donor descriptor, SHHBd, as the first variable. Compounds with 3	
high SHHBd values are more likely to have poor oral absorption, especially if they are 4	
hydrophilic with ACDLogD10 below -0.76; unless their Hmin value is lower than 0.48. A 5	
high number of potential H-bond formations is detrimental to high oral absorption, which is 6	
cited in the literature11, 27, 39, 40. Hmin is the minimum hydrogen electrotopological-state value 7	
for all atoms in the drug molecule and shows the nature of the hydrogen atoms attached to the 8	
skeleton of the drug molecule and whether they are hydrogen bond donors41. Otherwise if the 9	
Hmin value is higher than 0.48 compounds with higher VAMP HOMO than -8.56 may still 10	
have high oral absorption, but the large majority of compounds have a lower HOMO energy 11	
value and therefore will be expected to be poorly-absorbed through the gastrointestinal 12	
system (node 14). On the left hand side of the tree (node 2), for compounds with low 13	
hydrogen bond donor ability (SHHBd ≤ 6.59), oral absorption is expected to be high, unless 14	
ACDlogD7.4 is low and xc3 is high (node 9). The descriptor xc3 is the third order cluster chi 15	
connectivity index. This Chi index encodes the number and branching of the molecule for a 16	
single branch point and in this tree, it indicates that branched molecules (of hydrophilic 17	
nature) have poor oral absorption42. It must be noted in Figure 5 in nodes 9 and 11, for 18	
example, that the effect of misclassification costs is altering the final terminal class node, 19	
showing the misclassification costs applied to reduce false positives is working. Moreover, 20	
for high ACDlog7.4 compounds (>-1.10) oral absorption would be poor if they have a high 21	
number of internal hydrogen bonding groups of three bond distance (SHBint3_Acnt). It is 22	
interesting to note those nodes in the tree after the first split using SHHBd were both logD 23	
molecular descriptors but at different pH values. LogD at different pH values is affected by 24	
the ionization of the compound and is related to the compound’s pka. For example, for 25	
logD10, which means the diffusion coefficient at pH10, any basic compounds at pH10 will be 26	
unionized, therefore will have higher logD10 values than acidic compounds which will 27	
remain ionized due to the higher pH, and in the case of intestinal absorption will then be not 28	
absorbed. This indicates that pH-dependent lipophilicity measure (logD) at different pH 29	
values are important in distinguishing between high and low absorption for acidic and basic 30	
compounds as well as characterizing the lipophilicity.  31	
 32	
In Figure 6, all the molecular descriptors have been described previously apart from polar 33	
surface area (PSA). This descriptor along with lipophilicity has been described as an 34	
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influential molecular descriptor in predicting passive intestinal absorption6, 43, 44. PSA is the 1	
area of the Van der Waals surface that arises from oxygen and nitrogen atoms or hydrogen 2	
atoms bound to these atoms. It is a polarity measure which is also related to size and has a 3	
negative correlation with intestinal absorption so the larger the PSA the lower the absorption. 4	
Mass has also been used in this tree and in accordance with Lipinski’s rule of five, but only 5	
with a slightly different cut off point of 537.23 Da27, 45.  6	
4. Discussion 7	
4.1 Comparing models 8	
There are many statistical measures for the assessment of the predictability of classification 9	
models. The most common in QSAR literature are overall accuracy accompanied by SP and 10	
SE. However it must be emphasized here that ‘accuracy’ reported in the literature as the ratio 11	
of all the correctly classified compounds is misleading when the datasets are highly skewed22, 12	
46, 47. In other words, due to the majority of highly-absorbed compounds in the training and 13	
validation sets, the classification outcome of these compounds disproportionately affects the 14	
overall accuracy: therefore accuracy will follow the same trend as the sensitivity values in the 15	
model and fail to take into account the specificity appropriately. For example, if a dataset 16	
contained 90% of highly-absorbed and 10% of poorly absorbed compounds, a trivial 17	
classifier would consist of predicting the highly-absorbed class (the majority class) for all 18	
compounds in the validation set. Such a trivial majority classifier – which does not involve 19	
any data analysis – would trivially achieve an overall accuracy of 90% (if accuracy is simply 20	
measured as (TP + TN) / (TP + TN + FP + FN)). However, this high accuracy is misleading. 21	
Although the majority classifier achieved perfect prediction for the high absorption class, it 22	
achieved no correct predictions for the poorly –absorbed class. This example clearly shows a 23	
weakness of the overall accuracy measure, which is not an appropriate measure to use when 24	
the class distribution is very unbalanced.  The use of SP × SE avoids the above problem in 25	
this scenario, since the trivial majority classifier would achieve a prediction of 0% by 26	
multiplying the sensitivity (100%) and specificity (0%), and therefore would show the 27	
majority classifier’s ability to classify both classes as poor. A measure of 0% accuracy for the 28	
majority classifier is also intuitively fair; since that classifier is not even taking a look at the 29	
value of the descriptors (it just counts the number of compounds in each class). In summary, 30	
the overall accuracy as defined in the literature is an incorrect measure of accuracy in 31	
problems with very unbalanced class distributions, like the dataset in this work. In this work, 32	
to overcome the problem, the better accuracy measure of SP × SE was used as the measure of 33	
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the overall accuracy. This measure is a better representation of a models’ predictability, as it 1	
is affected the same way by false negatives as by false positives, and should be used in 2	
measuring the overall accuracy of a classification model. Other measures such as the 3	
Matthew’s correlation coefficient (MCC)48, kappa statistic49 and Youden’s J statistic50 to 4	
name a few have been used in the literature, with the choice of which one to use being 5	
subjective, with each measure having advantages and disadvantages51, 52. Youden’s index or J 6	
statistic50 is used frequently for medical diagnosis tests and is defined as 1 – (SE + SP). 7	
Kappa has been introduced as a chance-corrected measure of accuracy49 but it uses the 8	
overall accuracy in the calculation, which may not be suitable in this case since it will have a 9	
higher contribution from the majority highly absorbed class. MCC is another useful measure 10	
frequently used in QSAR and although it uses all four numbers (TP, TN, FP, FN), it requires 11	
normalized distribution and may give controversial results, for example when there are very 12	
few FP but also there are very few TPs52. We used SP × SE on the grounds that it is a simple 13	
measure with a clear interpretation and gives an overall fair measure of model performance 14	
without being affected by the class distribution bias. 15	
 16	
As stated previously, a direct comparison between the two different training sets is not a fair 17	
comparison due to the different class distributions of TS1, the balanced set, and TS2, the set 18	
biased towards highly-absorbed compounds. Nevertheless, it can be seen that TS1 in the 19	
majority of cases leads to higher specificity when misclassification costs are equal for FN and 20	
FP. TS2 gave higher sensitivity in all cases, which is expected due to the bias of the training 21	
set towards highly-absorbed compounds. It has been cited that the rule of five can give rise to 22	
false positives and could be a possible explanation why the specificity is lower for this model 23	
even with a balanced training set27, 53, 54.  24	
When misclassification costs are applied to either TS1 or TS2 to reduce false positives, 25	
specificity improves for both training sets. Moreover, it can be seen in Table 3 that the use of 26	
4:1 misclassification costs for FP:FN leads to improved models for TS2 with better SP × SE 27	
values. This finding shows that using misclassification costs can overcome a dataset bias by 28	
increasing specificity. 29	
In this paper we compared the effect of allowing the software to pick the most significant 30	
descriptors from all 215 descriptors used or from a smaller subset of descriptors previously 31	
selected as significant by stepwise regression analysis or those related to Lipinski’s rule of 32	
five. Table 2 shows that model 10 achieved the lowest value CNMI of 0.165 and the highest 33	
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SP × SE of 0.686 using descriptor set 1. The next best CNMI was again achieved by 1	
descriptor set 1 with a value of 0.188 (model 6); this model also obtained the highest 2	
specificity of 0.925 when misclassification costs were applied to reduce false positives. From 3	
Table 2 it is interesting to see that in several cases the CNMI values are higher for C&RT 4	
models using all descriptors compared with those models using smaller descriptor sets 5	
selected by feature selection techniques, meaning that there are more misclassification errors 6	
when allowing the C&RT analysis to pick significant descriptors from the 215 available. This 7	
could show that using linear stepwise regression to select a smaller subset of significantly 8	
relevant molecular descriptors to intestinal absorption beforehand can be advantageous as 9	
often models are produced with fewer misclassifications. The most accurate models for TS2 10	
(Table 3) are models 16 and then 17 which was developed using all descriptors or descriptor 11	
set 3. The fact that using all descriptors works well for TS2 but for TS1 prior descriptor 12	
selection is best, suggests that C&RT can be an efficient descriptor selection method when a 13	
large dataset is used (517 vs 94 compounds in TS2 and TS1, respectively). 14	
In the study for TS1 containing 94 compounds, a validation set containing 89 compounds has 15	
been used which mirrors the balanced data distribution of the training set. By balancing the 16	
validation set too it gives a fair representation of the models’ predictive performance. As an 17	
additional test the predictive performance of the models was investigated for a new validation 18	
set containing all the compounds not used in the training set. It must be noted that the 19	
additional validation set compounds are all highly-absorbed with the exception of two 20	
compounds. Therefore this validation set is biased. The results of this work can be found in 21	
Table 4. 22	
Table 4. The validation results of C&RT Classification models obtained using TS1 for all the 23	
remaining compounds not used in training 24	
Model Cost           FP:FN 
Descriptor 
Set 
N 
validation 
set 
SP x SE SE SP CNMI 
1 
1:1 
ALL 496 0.647 0.869 0.745 0.143 
2 1 521 0.730 0.852 0.857 0.148 
3 2 521 0.728 0.887 0.820 0.119 
4 4 521 0.341 0.898 0.380 0.152 
5 
2:1 
ALL 496 0.510 0.800 0.638 0.131 
6 1 521 0.712 0.775 0.918 0.115 
7 2 521 0.685 0.856 0.800 0.089 
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8 4 521 0.654 0.909 0.720 0.072 
9 
1:2 
ALL 496 0.673 0.855 0.787 0.258 
10 1 521 0.701 0.881 0.796 0.214 
11 2 521 0.657 0.887 0.740 0.208 
12 4 521 0.497 0.887 0.560 0.224 
FP = False positive; FN = False negative; SE= Sensitivity, SP = Specificity; CNMI = Cost normalised 1	
misclassification index; N validation is the number of validation set compounds that was predicted by the model 2	
According to Table 4  the best models according to SP × SE were those using descriptor set 1 3	
(models 2, 6 and 10), which corresponds to the results seen earlier for the smaller balanced 4	
validation set (Table 2 Model 10).  5	
4.2 Discussion of the related literature  6	
	7	
Summary tables in the literature detail the accuracy, specificity and sensitivity of 8	
classification work carried out by previous studies55-57. In particular Talevi et al (2011) has 9	
compiled a summary table summarising classification studies of intestinal absorption over the 10	
past decade. To compare the models obtained in this work with the literature is a very 11	
difficult task. There is lack of compound information and data distribution and a lack of 12	
consistency in the literature with regards to validation techniques and more importantly how 13	
the overall accuracy of the models are measured58-60. To directly compare our work with 14	
others in the literature all the information as described previously would be needed to mimic 15	
conditions regarding the dataset to enable comparison of the models, however this is not 16	
freely available61. 17	
 18	
The number of compounds in the datasets in the literature should be considered when 19	
assessing the model performances. Small datasets may achieve high prediction accuracy 20	
within the chemical space of the dataset, however will lack generalization to new chemical 21	
compounds. In the study by Niwa et al (2003), using 67 compounds achieved 100% correct 22	
classification for the training set, however this dropped to 80% for the external prediction set 23	
of 12 compounds. It must be highlighted that the main misclassification in Niwa et al’s model 24	
was for the poorly-absorbed compounds, which were represented inadequately in Niwa’s 25	
dataset47. As a result, the overall accuracy of Niwa et al’s model as calculated using our 26	
accuracy measurement (SP × SE) yields a value of 0.667. This is a reoccurring problem with 27	
the other datasets in the literature that we considered7, 8, 17. Poorly-absorbed compounds are 28	
predicted better using our models due to the larger representation of this class in our TS1 29	
training set and/or the use of varying misclassification costs. 30	
25	
	
 1	
Perez et al (2004)62 used linear discriminant analysis to classify a dataset of 209 compounds 2	
with training and validation set of 82 and 127 compounds respectively. This paper created 3	
two models, one which focussed on classification of %HIA using a threshold of ≤30% HIA 4	
and the other focussing on classification using a threshold of >80% HIA. Both training and 5	
validation sets are heavily biased towards highly-absorbed compounds and the results reflect 6	
this. Higher sensitivity values of 0.955 and 0.835 and much lower specificity values of 0.765 7	
and 0.722 for the threshold of ≤30% and >80% respectively.  8	
 9	
As stated before, in most studies the accuracy and sensitivity results are higher than the 10	
specificity values, due to the under-representation of poorly-absorbed compounds22, 46, 47. The 11	
one exception to this was obtained by Hou et al (2007) who obtained higher specificity than 12	
sensitivity in the validation set. However only five compounds in their validation set was 13	
defined as poorly-absorbed. Deconinck et al (2005) carried out C&RT analysis using Splus 14	
software on a smaller subset of the dataset compiled by Hou et al (2007). Deconinck achieved, 15	
using C&RT as a variable selection classification technique using a validation set of 27 16	
compounds, an overall prediction accuracy of 85%. However this validation set only 17	
contained highly-absorbed compounds and therefore only sensitivity values could be 18	
considered22. 19	
 20	
Lipinski’s rule of five is a qualitative rule based model which indicates that poor absorption 21	
is highly likely when two or more of the rules are broken. It has been criticised for having a 22	
high rate of false positives53, 54. With this work, descriptors describing Lipinski’s rule of five 23	
plus the number of rotatable bonds allowed a qualitative evaluation of Lipinski’s rule of five 24	
via C&RT analysis. Using Lipinski’s rule of five in its original form (if 2 or more rules were 25	
violated indicating poor absorption) specificity was 0.425 and 0.400 for the validation sets of 26	
TS1 and TS2 respectively. By incorporating these descriptors (descriptor set 4) in C&RT, for 27	
TS1 upon using higher misclassification costs to reduce false positives the specificity was 28	
0.750 and for TS2 specificity was 0.600. Using misclassification costs to reduce false 29	
positives, an improvement to Lipinski’s rules using misclassification costs was made possible.  30	
 31	
The descriptors selected in the models can be interpreted according to the known mechanisms 32	
involved in the absorption process. Table 5 gives a summary of all the molecular descriptors 33	
used in the selected models of 9, 10, 16 and 17. The most common molecular descriptors 34	
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used in the best models were descriptors of hydrogen bonding (such as SHHBd, SHBint2), 1	
log D at various pH values which is related to lipophilicity and acid/base property, 2	
ACD_Density which is related to the number of heteroatoms in the molecules, and polar 3	
surface area (PSA) which has been cited as a molecular descriptor relating to polarity and 4	
size 20, 63. Other important molecular attributes are size related parameters. These are in 5	
agreement with the literature indicating that the molecular descriptors important to intestinal 6	
absorption are those related to lipophilicity, hydrogen bonding, polarity, ionization, and size45, 7	
60, 63. From considering the molecular descriptors utilised in the models in this work overall, 8	
no matter what training set used, molecular descriptors that described these parameters which 9	
are shown in the literature to be important for intestinal absorption were present in the best 10	
models30, 64.  11	
 12	
Table 5. Molecular descriptors used in the selected models (9, 10, 16 and 17) 13	
Type of descriptor Name of descriptor 
Number of 
occurrences in 
selected models 
Hydrogen bonding 
SHHBd 3 
ABSQ 1 
ACD_Density 2 
SHBint2 1* 
SHBint3_Acnt 1 
Hmin 1 
ACD_PSA 1* 
Lipophilicity 
ACD logD 5.5 2* 
ACD logD 7.4 1 
ACD logD 10 1 
ACD logD 2 1 
Size 
xvch7 1 
Inertia moment 2 (size) 1 
xc3 1 
Mass 1 
Polarity/ 
polarizability 
VAMP HOMO 2 
Total dipole moment 1 
Spc polarizability 1 
Acidity FiA1 1 
* occurred more than once in a single tree model 14	
 15	
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5 Conclusion 1	
Class imbalance occurs frequently in QSAR and drug discovery datasets14, 65-67. This could be 2	
for a number of reasons; however in this context it is due to lack of publically available data 3	
for the minority class, poorly-moderately absorbed compounds, in the literature.	 The aim of 4	
this work was to improve the class prediction of poorly absorbed compounds by the use of 5	
varying misclassification costs in C&RT analysis. This was analysed using two training sets, 6	
the one selected by under-sampling the majority class (TS1), or the training set selected 7	
randomly and hence biased towards highly-absorbed compounds (TS2). The comparison 8	
between C&RT descriptor selection and pre-selecting a small subset of molecular descriptors 9	
using statistical techniques or rule-based models was also considered. In this work, in order to 10	
effectively compare the models, the traditional ‘overall accuracy’ measure was scrutinised 11	
and better measures of prediction accuracy, SP × SE, and cost normalised misclassification 12	
index (CNMI), were suggested and incorporated. 13	
Under-sampling the majority class to create a balanced training set produced models that had 14	
high predictive power for the prediction of poorly-absorbed compounds. The randomly 15	
selected training set (TS2) as expected had high predictive power for highly-absorbed 16	
compounds with high sensitivity values, but this was accompanied by low specificity values. 17	
This conclusion conforms to the previous work using regression and discriminant analysis 18	
classification26.  19	
The use of misclassification costs led to improvements in prediction accuracy. Even though 20	
there is no general consensus to reduce false positives or false negatives from the literature, 21	
this work shows that misclassification costs can be applied to reduce false positives or false 22	
negatives. Other considerations such as poor solubility and carrier mediated transport systems 23	
can play a part in misclassification error rates in the models17. For the biased training set 24	
containing the majority high absorption class, applying higher costs for the misclassification 25	
of false positives improved specificity in all cases. The imbalanced dataset can be utilised 26	
without removing compounds as an advantage for improved sensitivity as it will already be 27	
biased towards high absorption compounds. Therefore, varying ratios of misclassification 28	
costs can be used as a vital and effective tool to overcome class imbalance, which is a 29	
recurring problem in drug discovery datasets.  30	
The comparison between using all descriptors for the C&RT or to use a smaller subset of 31	
molecular descriptors suggests that the descriptors selected by stepwise linear regression may 32	
28	
	
achieve better prediction, but this cannot be generalized and descriptor selection by C&RT 1	
may work just as well when a large training set is used, e.g. TS2. 2	
In conclusion, reasonably interpretable user friendly models that can be easily understood and 3	
utilised for specific purposes has been achieved by using two strategies, under-sampling the 4	
majority class of the training set and misclassification costs, to overcome class imbalance of 5	
the dataset. 6	
 7	
Supporting Information 8	
The molecular descriptor sets selected using stepwise regression analysis for different 9	
training sets (descriptor sets 1-3) and molecular descriptors used in Lipinski’s rule of five 10	
plus number of rotatable bonds (descriptor set 4) is described in the Supporting Information. 11	
This information is available free of charge via the Internet at http://pubs.acs.org. 12	
 13	
References 14	
1. Davis, A. M.; Keeling, D. J.; Steele, J.; Tomkinson, N. P.; Tinker, A. C. Components 15	
of successful lead generation. Curr. Top. Med. Chem. 2005, 5, 421-439. 16	
2. Gleeson, M. P.; Hersey, A.; Hannongbua, S. In-Silico ADME Models: A General 17	
Assessment of their Utility in Drug Discovery Applications. Curr. Top. Med. Chem. 2011, 11, 18	
358-381. 19	
3. Yu, H. S.; Adedoyin, A. ADME-Tox in drug discovery: integration of experimental 20	
and computational technologies. Drug Discovery Today. 2003, 8, 852-861. 21	
4. Chohan, K. K.; Paine, S. W.; Waters, N. J. Advancements in Predictive In Silico 22	
Models for ADME. Curr. Chem. Biol. 2008, 2, 215-228. 23	
5. Geerts, T.; Heyden, Y. V. In Silico Predictions of ADME-Tox Properties: Drug 24	
Absorption. Comb. Chem. High Throughput Screening. 2011, 14, 339-361. 25	
6. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction 26	
paradise? Nat. Rev. Drug Discovery. 2003, 2, 192-204. 27	
7. Wessel, M. D.; Jurs, P. C.; Tolan, J. W.; Muskal, S. M. Prediction of human intestinal 28	
absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 1998, 38, 29	
726-735. 30	
8. Zhao, Y. H.; Abraham, M. H.; Le, J.; Hersey, A.; Luscombe, C. N.; Beck, G.; 31	
Sherborne, B.; Cooper, I. Rate-limited steps of human oral absorption and QSAR studies. 32	
Pharm. Res. 2002, 19, 1446-1457. 33	
9. Oprea, T. I.; Allu, T. K.; Fara, D. C.; Rad, R. F.; Ostopovici, L.; Bologa, C. G. Lead-34	
like, drug-like or "pub-like": how different are they? J. Comput.-Aided Mol. Des. 2007, 21, 35	
113-119. 36	
29	
	
10. Yan, A.; Wang, Z.; Cai, Z. Prediction of Human Intestinal Absorption by GA Feature 1	
Selection and Support Vector Machine Regression. Int. J. Mol. Sci. 2008, 9, 1961-1976.  2	
11. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, 3	
N.; Stoner, C. L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective. 4	
Expert Opin. Drug Metab. Toxicol. 2006, 2, 591-608. 5	
12. Breiman, L., Bagging predictors. Mach. Learn. 1996, 24, 123-140. 6	
13. Breiman, L., Random forests. Mach. Learn. 2001, 45, 5-32. 7	
14. Blagus, R.; Lusa, L. Class prediction for high-dimensional class-imbalanced data. 8	
BMC Bioinformatics. 2010, 11. 9	
15. White, R. E. High-throughput screening in drug metabolism and pharmacokinetic 10	
support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 133-157. 11	
16. Beresford, A. P.; Segall, M.; Tarbit, M. H. In silico prediction of ADME properties: 12	
Are we making progress? Curr. Opin. Drug Discovery Dev. 2004, 7, 36-42. 13	
17. Klopman, G.; Stefan, L. R.; Saiakhov, R. D. ADME evaluation 2. A computer model 14	
for the prediction of intestinal absorption in humans. Eur. J. Pharm. Sci. 2002, 17, 253-263. 15	
18. Cummings, D., J. Pharmaceutical Drug Discovery: Designing the Blockbuster Drug. 16	
In Screening Methods for Experimentation in Industry, Drug Discovery, and Genetics, First 17	
edition; Dean, A.; Lewis, S., Eds. Springer: New York, 2006; pp 74-76. 18	
19. Rydzewski, M. R. Real World Drug Discovery A Chemist's Guide to Biotech and 19	
Pharmaceutical Research; First edition; Elsevier: Oxford, 2008. 20	
20. Hou, T. J.; Wang, J. M.; Zhang, W.; Xu, X. J. ADME evaluation in drug discovery. 7. 21	
Prediction of oral absorption by correlation and classification. J. Chem. Inf. Model. 2007, 47, 22	
208-218. 23	
21. Abraham, M. H.; Zhao, Y. H.; Le, J.; Hersey, A.; Luscombe, C. N.; Reynolds, D. P.; 24	
Beck, G.; Sherborne, B.; Cooper, I. On the mechanism of human intestinal absorption. Eur. J. 25	
Med. Chem. 2002, 37, 595-605. 26	
22. Deconinck, E.; Hancock, T.; Coomans, D.; Massart, D. L.; Vander Heyden, Y. 27	
Classification of drugs in absorption classes using the classification and regression trees 28	
(CART) methodology. J. Pharm. Biomed. Anal. 2005, 39, 91-103. 29	
23. Breiman, L.; Friedman, J.; Stone, C. J.; Olshen, R. A. Classification and Regression 30	
Trees. First edition; Chapman and Hall/CRC: Boca Raton, 1984. 31	
24. Tan, P. N.; Steinbach, M.; Kumar, V. Introduction to Data Mining. First edition; 32	
Pearson International Edition: Boston, 2006. 33	
25. Witten, I. H.; Frank, E.; Hall, M. A. Data Mining Practical Machine Learning Tools 34	
and Techniques. Third edition; Morgan Kaufmann Publishers: Burlington, 2011. 35	
26. Ghafourian, T.; Newby, D.; Frietas, A. A. The impact of training set data distributions 36	
for modelling of passive intestinal absorption. Int. J. Pharm. 2012, 436, 711-720. 37	
30	
	
27. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 1	
computational approaches to estimate solubility and permeability in drug discovery and 2	
development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25. 3	
28. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity - 4	
A Rapid Access to Atomic Charges. Tetrahedron. 1980, 36, 3219-3228. 5	
29. Pang, K. S. Modeling of intestinal drug absorption: Roles of transporters and 6	
metabolic enzymes (for the Gillette Review Series). Drug Metab. Dispos. 2003, 31, 1507-7	
1519. 8	
30. Turner, J. V.; Glass, B. D.; Agatonovic-Kustrin, S. Prediction of drug bioavailability 9	
based on molecular structure. Anal. Chim. Acta. 2003, 485, 89-102. 10	
31.        Agatonovic-Kustrin, S.; Beresford, R.; Yusof, A. P. M. Theoretically-derived 11	
molecular descriptors important in human intestinal absorption. J. Pharm. Biomed. Anal. 12	
2001, 25, 227-237. 13	
32. Sai, Y.; Tsuji, A. Transporter-mediated drug delivery: recent progress and 14	
experimental approaches. Drug Discovery Today. 2004, 9, 712-720. 15	
33. Lin, W. W.; Buolamwini, J. K. Synthesis, flow cytometric evaluation, and 16	
identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 17	
1 inhibitors. J. Med. Chem. 2007, 50, 3906-3920. 18	
34. Wanchana, S.; Yamashita, F.; Hara, H.; Fujiwara, S. I.; Akamatsu, M.; Hashida, M. 19	
Two- and three-dimensional QSAR of carrier-mediated transport of beta-lactam antibiotics in 20	
Caco-2 cells. J. Pharm. Sci. 2004, 93, 3057-3065. 21	
35. Varma, M. V. S.; Obach, R. S.; Rotter, C.; Miller, H. R.; Chang, G.; Steyn, S. J.; El-22	
Kattan, A.; Troutman, M. D. Physicochemical Space for Optimum Oral Bioavailability: 23	
Contribution of Human Intestinal Absorption and First-Pass Elimination. J. Med. Chem. 2010, 24	
53, 1098-1108. 25	
36. Zakeri-Milani, P.; Tajerzadeh, H.; Islambolchilar, Z.; Barzegar, S.; Valizadeh, H. The 26	
relation between molecular properties of drugs and their transport across the intestinal 27	
membrane. Daru, J. Pharm. Sci. 2006, 14, 164-171. 28	
37. Comer, J. E. A. High-throughput Measurement of log D and pka. In Drug 29	
Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability 30	
(Methods and Principles in Medicinal Chemistry), First Edition; van de Waterbeemd,; 31	
Lennernäs, H.; Artursson, P.; Mannhold, R.; Kubinyi, H.; Folkers, G. Eds. Wiley-VCH: 32	
Weinheim, 2003; Vol. 18, p 23. 33	
38. Kerns, E. H.; Di, L. Drug like properties: Concepts, Structure Design and Methods 34	
from ADME to Toxicity Optimisation. First edition; Academic Press Elsevier: Burlington, 35	
2008. 36	
39. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor 37	
permeability. J. Pharmacol. Toxicol. Methods. 2000, 44, 235-249. 38	
40. Yu, K.; Chen, F.; Li, C. Absorption, Disposition, and Pharmacokinetics of Saponins 39	
from Chinese Medicinal Herbs: What Do We Know and What Do We Need to Know More? 40	
Curr. Drug Metab. 2012, 13, 577-598. 41	
31	
	
41. Wang, Y.; Li, Y.; Ding, J.; Jiang, Z.; Chang, Y. Estimation of bioconcentration 1	
factors using molecular electro-topological state and flexibility. SAR QSAR Environ. Res. 2	
2008, 19, 375-395. 3	
42. Hall, L. H.; Kier, L. B. The Molecular Connectivity Chi Indices and Kappa Shape 4	
Indices in Structure-Property Modeling. In Reviews in Computational Chemistry, Boyd, D.; 5	
Lipkowitz, K., Eds. VCH: New York, 1991; pp 384–385. 6	
43. Palm, K.; Luthman, K.; Ungell, A. L.; Strandlund, G.; Artursson, P. Correlation of 7	
drug absorption with molecular surface properties. J. Pharm. Sci. 1996, 85, 32-39. 8	
44. van de Waterbeemd, H.; Kansy, M. Hydrogen-Bonding Capacity and Brain 9	
penetration. Chimia 1992, 46, 299-303. 10	
45. Yang, Y. D.; Engkvist, O.; Llinas, A.; Chen, H. M. Beyond Size, Ionization State, and 11	
Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, 12	
Excretion, and Toxicity for Druglike Compounds. J. Med. Chem. 2012, 55, 3667-3677. 13	
46. Deconinck, E.; Zhang, M. H. H.; Coomans, D.; Vander Heyden, Y. Classification tree 14	
models for the prediction of blood-brain barrier passage of drugs. J. Chem. Inf. Model. 2006, 15	
46, 1410-1419. 16	
47. Niwa, T. Using general regression and probabilistic neural networks to predict human 17	
intestinal absorption with topological descriptors derived from two-dimensional chemical 18	
structures. J. Chem. Inf. Comput. Sci. 2003, 43, 113-119. 19	
48. Matthews, B. W. Comparison of the predicted and observed secondary structure of T4 20	
phage lysozyme. Biochim. Biophys. Acta. 1975, 405, 442-451. 21	
49. Cohen, J. Weighed kappa: Nominal scale agreement with provision for scaled 22	
disagreement or partial credit. Psychol. Bull. 1968, 70, 213-220. 23	
50. Youden, W. J. Index for rating diagnostic tests. Cancer. 1950, 3, 32-35. 24	
51. Gleeson, M. P.; Modi, S.; Bender, A.; Robinson, R. L. M.; Kirchmair, J.; 25	
Promkatkaew, M.; Hannongbua, S.; Glen, R. C. The Challenges Involved in Modeling 26	
Toxicity Data In Silico: A Review. Curr. Pharm. Des. 2012, 18, 1266-1291. 27	
52. Baldi, P.; Brunak, S.; Chauvin, Y.; Andersen, C. A. F.; Nielsen, H. Assessing the 28	
accuracy of prediction algorithms for classification: an overview. Bioinformatics. 2000, 16, 29	
412-424. 30	
53. Andrews, C. W.; Bennett, L.; Yu, L. X. Predicting human oral bioavailability of a 31	
compound: Development of a novel quantitative structure-bioavailability relationship. Pharm. 32	
Res. 2000, 17, 639-644. 33	
54. Zhu, J. Y.; Wang, J. M.; Yu, H. D.; Li, Y. Y.; Hou, T. J. Recent Developments of In 34	
Silico Predictions of Oral Bioavailability. Comb. Chem. High Throughput Screening. 2011, 35	
14, 362-374. 36	
55. Suenderhauf, C.; Hammann, F.; Maunz, A.; Helma, C.; Huwyler, J. Combinatorial 37	
QSAR Modeling of Human Intestinal Absorption. Mol. Pharmaceutics. 2011, 8, 213-224. 38	
32	
	
56. Hou, T. J.; Wang, J. M.; Zhang, W.; Wang, W.; Xu, X. Recent advances in 1	
computational prediction of drug absorption and permeability in drug discovery. Curr. Med. 2	
Chem. 2006, 13, 2653-2667. 3	
57. Talevi, A.; Goodarzi, M.; Ortiz, E. V.; Duchowicz, P. R.; Bellera, C. L.; Pesce, G.; 4	
Castro, E. A.; Bruno-Blanch, L. E. Prediction of drug intestinal absorption by new linear and 5	
non-linear QSPR. Eur. J. Med. Chem. 2011, 46, 218-228. 6	
58. Stouch, T. R.; Kenyon, J. R.; Johnson, S. R.; Chen, X. Q.; Doweyko, A.; Li, Y. In 7	
silico ADME/Tox: why models fail. J. Comput.-Aided Mol. Des. 2003, 17, 83-92. 8	
59. The, H. P.; Gonzalez-Alvarez, I.; Bermejo, M.; Sanjuan, V. M.; Centelles, I.; 9	
Garrigues, T. M.; Cabrera-Perez, M. A. In Silico Prediction of Caco-2 Cell Permeability by a 10	
Classification QSAR Approach. Mol. Inf. 2011, 30, 376-385. 11	
60. Zhao, Y. H.; Le, J.; Abraham, M. H.; Hersey, A.; Eddershaw, P. J.; Luscombe, C. N.; 12	
Boutina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J. A. Evaluation of human intestinal 13	
absorption data and subsequent derivation of a quantitative structure-activity relationship 14	
(QSAR) with the Abraham descriptors. J. Pharm. Sci. 2001, 90, 749-784. 15	
61. Davis, A. M.; Brunea, P. In Silico Prediction of Solubility In Drug Bioavailability: 16	
Estimation of Solubility, Permeability, Absorption and Bioavailability (Methods and 17	
Principles in Medicinal Chemistry), First edition.; Van de Waterbeemd, H.; Lennernäs, H.; 18	
Artursson, P.; Mannhold, R.; Kubinyi, H.; Folkers, G., Eds. Wiley-VCH: Weinheim, 2003; 19	
Vol. 18, pp 53-56. 20	
62. Perez, P. A. C.; Sanz, M. B.; Torres, L. R.; Avalos, R. C.; Gonzalez, M. P.; Diaz, H. 21	
G. A topological sub-structural approach for predicting human intestinal absorption of drugs. 22	
Eur. J. Med. Chem. 2004, 39, 905-916. 23	
63. Wegner, J. K.; Frohlich, H.; Zell, A. Feature selection for descriptor based 24	
classification models. 2. Human intestinal absorption (HIA). J. Chem. Inf. Comput. Sci. 2004, 25	
44, 931-939. 26	
64. Yen, T. E.; Agatonovic-Kustrin, S.; Evans, A. M.; Nation, R. L.; Ryand, J. Prediction 27	
of drug absorption based on immobilized artificial membrane (IAM) chromatography 28	
separation and calculated molecular descriptors. J. Pharm. Biomed. Anal. 2005, 38, 472-478. 29	
65. Van Hulse, J.; Khoshgoftaar, T. Knowledge discovery from imbalanced and noisy 30	
data. Data Knowl. Eng. 2009, 68, 1513-1542. 31	
66. Zhang, Q. Y.; Hughes-Oliver, J. M.; Ng, R. T. A Model-Based Ensembling Approach 32	
for Developing QSARs. J. Chem. Inf. Model. 2009, 49, 1857-1865. 33	
67. Li, Q. L.; Wang, Y. L.; Bryant, S. H. A novel method for mining highly imbalanced 34	
high-throughput screening data in PubChem. Bioinformatics. 2009, 25, 3310-3316. 35	
33	
	
For	Table	of	Contents	Use	Only	1	
	2	
	
Coping with unbalanced class datasets in oral 
absorption models 
	
Danielle Newby, Alex. A. Freitas, Taravat 
Ghafourian*	
	
	
